Acrotech Biopharma Inc.
Belinostat(Acrotech Biopharma Inc.)은 Adult T-cell Leukemia-Lymphoma 표적 세포·유전자 치료로, Breast Adenocarcinoma; Metastatic Breast Carcinoma 영역에서 개발·상용화 중입니다. 작용기전: target only two of these pathway. Phase 1 안전성·PK 탐색 단계입니다. OS: 17.9. PK: t½ 1.1 h. 차별점: novel HDACis by replacing the Zinc Binding Groups (ZBGs) and caps of known pan-HDAC inhibitors with respective bioisosteric f.
Adult T-cell Leukemia-Lymphoma
Breast Adenocarcinoma; Metastatic Breast Carcinoma
Discontinued
CAR-T) therapy directed at the CD19 antigen expressed on the cell
Vedotin, and Belinostat
linkers while substituting caps and ZBGs
retroviral Therapy (ART) in the management of viral replication and infection, HIV latency
novel HDACis by replacing the Zinc Binding Groups (ZBGs) and caps of known pan-HDAC inhibitors with respective bioisosteric f
target only two of these pathway
cytokine release syndrome at dose level 4 (adavosertib 225 mg/day; belinostat 1000 mg/m 2 ) qualified as a
DNA damage
Biomarker for Prognosis and Targeted Therapy in Diffuse Large B-cell Lymphoma
downregulation of stem cell and proliferation markers
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Acrotech Biopharma Inc.
Belinostat(Acrotech Biopharma Inc.)은 Adult T-cell Leukemia-Lymphoma 표적 세포·유전자 치료로, Breast Adenocarcinoma; Metastatic Breast Carcinoma 영역에서 개발·상용화 중입니다. 작용기전: target only two of these pathway. Phase 1 안전성·PK 탐색 단계입니다. OS: 17.9. PK: t½ 1.1 h. 차별점: novel HDACis by replacing the Zinc Binding Groups (ZBGs) and caps of known pan-HDAC inhibitors with respective bioisosteric f.
Adult T-cell Leukemia-Lymphoma
Breast Adenocarcinoma; Metastatic Breast Carcinoma
Discontinued
CAR-T) therapy directed at the CD19 antigen expressed on the cell
Vedotin, and Belinostat
linkers while substituting caps and ZBGs
retroviral Therapy (ART) in the management of viral replication and infection, HIV latency
novel HDACis by replacing the Zinc Binding Groups (ZBGs) and caps of known pan-HDAC inhibitors with respective bioisosteric f
target only two of these pathway
cytokine release syndrome at dose level 4 (adavosertib 225 mg/day; belinostat 1000 mg/m 2 ) qualified as a
DNA damage
Biomarker for Prognosis and Targeted Therapy in Diffuse Large B-cell Lymphoma
downregulation of stem cell and proliferation markers
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.